Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Codiak Biosciences Inc.
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2015
Status: Out of Business
BioCentury | Apr 3, 2025
Product Development
Exosomes are finding new life as the field solves for manufacturing
Can exosomes step in as delivery vehicles where LNPs fall short?
BioCentury | Nov 13, 2024
Management Tracks
Rubedo names Frederick Beddingfield CEO
Plus: Kian Teik Beh succeeds Frederick Chew at A*STAR, and updates from Climb Bio, DiogenX, Arch, SR One and Koneksa
BioCentury | Sep 27, 2024
Discovery & Translation
Three tensions in early-stage translation: BioCentury Grand Rounds
Across disciplines, researchers are navigating trade-offs in advancing translation that boil down to scope versus focus
BioCentury | Sep 9, 2024
Management Tracks
Doug Williams takes on CAR T cell access as TriArm CEO
Veteran of Biogen, Sana to head cross-border company TriArm Therapeutics
BioCentury | Apr 19, 2024
Management Tracks
Doug Williams leaving Sana
Plus: Baptista joins SmartCella and updates from LifeArc and Gain
BioCentury | Jun 8, 2023
Management Tracks
New CFO, commercial officer at Pulmocide
Plus: Helmling named CBO at eTheRNA, and updates from EpimAb, Ring, Amarna, XNK and more
BioCentury | May 9, 2023
Management Tracks
Hofmann named CEO at Vicinitas
Plus: New COO, CTO at Guardant, Scangos joins Voyager’s board, and updates from Mariana, Merck KGaA, CymaBay and more
BioCentury | Apr 10, 2023
Product Development
Williams, Meininger tasked with validating Sana’s platforms in the clinic
The ex-Codiak and Vertex execs bring translational and clinical expertise in new modalities
BioCentury | Mar 28, 2023
Product Development
March 27 Quick Takes: Big gain for Novartis on Kisqali readout
Plus: SR One closes $600M second fund and updates from Vertex, CRISPR; Merck KGaA, Pfizer and more
BioCentury | Mar 3, 2023
Management Tracks
Karen Massey succeeding Woods as argenx COO
Plus: BioCentury’s Bernstein joins C-Path board and updates from Marengo and Certara
Items per page:
1 - 10 of 89